90 results about "Neuropeptide" patented technology

Disclosed are hybrid polypeptides that agonize GIP, GLP-1 and neuropeptide Y2 (NPY2) receptors and their medical use in the treatment of a variety of diseases, conditions or conditions, such as obesity, diabetes and / or NASH. The polypeptides have the general structure Z1-Z2-Z3 wherein Z1 is a hybrid polypeptide that provides GIPR and GLP1R agonism, Z2 is a linker, and Z3 is a polypeptide that provides hY2R agonism.

The invention relates to the technical field of skin care products, in particular to a stress relieving composition containing camellia flower extract and application of the stress relieving composition. The composition comprises the following components: a camellia extract, a porphyridium extract, an anise leaf extract and a vetiver extract, and the four components cooperate to regulate and control, completely intervene in a neuroinflammation path, block transmission of nerve stimulation signals, reduce release of neuropeptides and inflammatory factors, repair damaged nerve barriers and improve neurological function. The effect of comprehensively relieving the skin sensitivity reaction is achieved. The composition not only has a faster and more durable effect, but also has good safety and applicability, and is especially suitable for protecting and conditioning high-sensitivity skin and skin in an extreme environment.

The invention discloses a double-anchoring enzyme response polypeptide as well as a preparation method and application thereof, and the preparation method comprises the following steps: introducing a gelatinase response sequence GPLGV between an antibacterial peptide HHC36 and a tissue repair promoting peptide, and carrying out double-end azido modification to obtain the double-anchoring enzyme response polypeptide. The peptide for promoting tissue repair can be cell adhesion peptide, osteogenic peptide, neurogenic peptide, angiogenic peptide and other functional polypeptides. The polypeptide is double-anchored on the surface of the titanium sheet through double-end azide modification. The activity of the polypeptide is closely related to the degree of freedom of the polypeptide, two ends of the polypeptide are fixed on the surface by azide groups in a non-infection environment, cell membranes cannot be destroyed through model antibacterial mechanisms such as annular holes, and at the moment, osteogenic activity is expressed. In a bacterial infection environment, gelatinase secreted by bacteria can enable antibacterial polypeptide to be unilaterally released to obtain chain segment freedom, and the antibacterial property is improved, so that antibacterial / osteogenesis functional switching of bacterial gelatinase responsiveness is realized, and a functionalized titanium-based implant surface is constructed.

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The invention relates to an anti-epileptic polypeptide coupling medicine and a preparation method and application thereof, the polypeptide coupling medicine comprises an Fmoc protecting group, a permeation accelerating peptide and a cell penetrating peptide which are sequentially connected from the N end to the C end, and the permeation accelerating peptide is connected with an anti-epileptic medicine molecule. According to the invention, by fully utilizing the treatment requirements of epileptic seizure and the technical advantages of intranasal drug delivery, through the collaborative design of the protecting group, the functional polypeptide sequence and the anti-epileptic drug, the defects of poor brain targeting property, easy cyclization of a polypeptide carrier, low intranasal delivery efficiency and the like of the traditional anti-epileptic drug are overcome, non-invasive, efficient and low-toxicity epilepsy treatment is realized, and the application prospect is wide. And the preparation process is simplified, the clinical transformation requirement is met, and meanwhile, a new strategy is provided for non-invasive brain delivery of neuropeptide drugs.

The present invention relates to insect neuropeptide compounds of the family of pyroglutamic peptides and analogs thereof having activity against insects, such as Hemiptera, Diptera, Lepidoptera, Blattaria and / or Coleoptera insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

A small molecule compound SPAM1 for up-regulating neuropeptide PACAP and receptor PAC1-R thereof, a method for preparing the same and use of the same; the SPAM1 has a structure of formula (I), wherein R=none, H2O or HCl; SPAM1 has small molecular weight, and can efficiently cross biological barriers including a blood-brain barrier, a blood-testis barrier etc; SPAM1 up-regulates the expression of the neurotransmitter / neuromodulator PACAP secreted by hypothalamus-pituitary and the specific receptor thereof, and acts on the glands downstream of the gonadal axis and the adrenal axis, thereby exerting comprehensive regulation effects; and SPAM1 specifically targets the PAC1-R1, and only acts on cells and tissues of nervous and endocrine systems naturally expressing the PAC1-R, thereby producing fewer side effects. Accordingly, SPAM1 is a novel small molecule compound medicament for effectively treating and preventing function decline and disorders of nervous, endocrine and immune systems closely related to neuropeptide PACAP.

The present invention relates to analogues of insect neuropeptides that are active against insects, such as Diptera, Hemiptera, Blattodea and / or Lepidoptera, and to the use of these as insect control agents (e.g., insecticides) and plant protection agents.

The invention relates to the technical field of medicines, in particular to application of a neuropeptide Y1 receptor antagonist in preparation of a hereditary polycystic kidney disease treatment medicine. The neuropeptide Y1 receptor antagonist is selected from a compound BIBO3304 which plays a role in blocking combination of neuropeptide Y (NPY) and a Y1 receptor subtype thereof. On the basis that early-stage histopathology, high-throughput sequencing, cytobiology and molecular biology are combined with in-vitro cell culture and in-vivo animal experiments, the potential treatment effect of the neuropeptide Y1 receptor antagonist in preparation of hereditary polycystic kidney disease treatment drugs is provided, and a new basis is provided for hereditary polycystic kidney disease treatment.

The present invention discloses a neuropeptide prediction method and system based on multimodal features and twin networks, belonging to the field of neuropeptide prediction technology, comprising the following steps: S1: constructing a benchmark dataset; S2: encoding NPs; S3: constructing a twin network module; S4: constructing a protein language module; S5: constructing a prediction model; and S6: using the model for prediction. The present invention constructs a balanced dataset and, based on this dataset, utilizes four encoding methods (token embedding encoding, word2vec embedding encoding, manual feature encoding, and protein language embedding encoding) to obtain feature vectors of neuropeptide sequences. The prediction model is constructed by combining the twin network module and the protein language module, enabling accurate identification of neuropeptides (NPs) with an accuracy exceeding that of currently available prediction methods.

The present invention relates to triple agonists of the GLP1 / GIP / NPY2 receptor. Disclosed are hybrid polypeptides that agonize GIP, GLP-1 and neuropeptide Y2 (NPY2) receptors and their medical use in the treatment of a variety of diseases, conditions or conditions, such as obesity, diabetes and / or NASH. The polypeptides have the general structure Z1-Z2-Z3 wherein Z1 is a hybrid polypeptide that provides GIPR and GLP1R agonism, Z2 is a linker, and Z3 is a polypeptide that provides hY2R agonism.

The invention relates to a neuropeptide identification method and system based on comparative learning and a cross attention mechanism. The method comprises the steps that a data set is acquired and preprocessed to obtain a training data set; performing feature extraction on the training data set by using a feature coding strategy, a BLOSUM62 matrix and a protein language model ESM-2; performing feature representation through a bidirectional long-short-term memory network and a multi-scale convolutional neural network; obtaining two target vectors based on a cross attention mechanism, a multi-head attention mechanism and a feedforward neural network; and determining a contrast loss function, performing contrast learning on the two target vectors according to the contrast loss function, performing dimension reduction processing, constructing a neuropeptide identification model, and completing neuropeptide identification. Local details and global context information can be captured through various strategies and network models; by constructing the neuropeptide identification model, the model can more effectively capture the complex relationship between sequences and between samples, and the identification precision of neuropeptide is improved.

Failures in establishing trust during international conflict negotiations frequently result in warfare, as ideological differences often cannot be resolved through rational discourse alone. Empathy between opposing parties is essential for building trust, and oxytocin is recognized for its critical role in facilitating empathy, trust, inter-brain synchrony, and cooperative decision-making. However, prevailing scientific studies typically do not differentiate between the cis and trans isomers of oxytocin, despite evidence that only the trans isomer is pharmacologically active. The present invention provides methods for the separation and quantification of oxytocin isomers, with particular emphasis on the trans isomer's function in social synchrony and decision-making within conflict negotiation contexts. Additionally, the invention explores the role of extremely low frequency electromagnetic radiation permeating the human central nervous system interconnecting neurochemical changes among groups. These advances clarify the unique neuropeptide functions of oxytocin and enhance understanding of its impact on cooperation and conflict resolution.

To provide a composition of trophinetide. [Solution] This disclosure describes a compound of formula (I), its stereoisomers, by-compounds, pharmaceutical compositions, and methods for producing such compounds using silylating agents, as well as methods for producing compositions and products produced using such methods. More specifically, this disclosure describes the production of trophinetides and by-products, compositions, and products containing such compounds for pharmaceutical applications for the treatment of neurodegenerative or neurodevelopmental disorders. JPEG2026063085000110.jpg55147

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

The invention discloses an external composition which contains a traditional Chinese medicine composition, and the traditional Chinese medicine composition comprises fructus cnidii, radix sophorae flavescentis and cortex dictamni. The external composition can be applied to preparation of a regulating agent for regulating and controlling the reduction of the concentration of neuropeptide and / or histamine in blood. The external composition can act on a skin target area where pruritus occurs, the concentration of P substances, gastrin releasing peptide and histamine in blood can be regulated and controlled, and then the attack of symptoms such as pruritus and the like can be relieved or treated.

Compositions and methods for the control and treatment of obesity, metabolic disorders, nausea and vomiting using ODN peptides and synthetic derivatives thereof are disclosed.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

The present invention relates to natural or natural-like analogues of insect pyrokinin neuropeptide [Pyr]-AIMARPQVPRL-[NH2](SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran, blattodean and / or coleopteran insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

The invention provides a preparation process of a soothing and repairing type mask, and belongs to the technical field of cosmetics, an intelligent response type cell bionic delivery system is adopted, macrophage membrane vesicles serve as a carrier, a composite repairing kernel, epicatechin gallate, a neuropeptide P substance antagonist and idebenone are wrapped, and by means of the inflammation chemotaxis of a macrophage membrane, the soothing and repairing type mask is prepared. According to the present invention, the active component can actively target the inflammation region, the phase change release core is provided in the weakly acidic microenvironment with the pH value of 5.0-6.0, the targeting property and the permeation efficiency of the active component can be improved, the bottleneck of the traditional passive diffusion can be broken through, and compared with the conventional liposome or nanoparticle, the active component can be accurately delivered to the inflammation core region, the permeation rate can be improved by several times, and the carrier can directly reach the problem core region; according to the method, the utilization rate of effective components is greatly increased, a micro-ecology-immunity-nerve-physical barrier multi-dimensional and systematic synergistic repair network is constructed, full-path fundamental repair from immediate relieving to root strengthening is achieved, and immediate relieving and long-term barrier repair effects are provided.

The invention belongs to the technical field of nanoprobes, and relates to an iron-based polypeptide probe for regulating and controlling a mitochondrial function and application of the iron-based polypeptide probe in tumor inhibition drugs. The invention discloses an iron-based polypeptide probe for regulating and controlling a mitochondrial function, the iron-based polypeptide probe for regulating and controlling the mitochondrial function comprises superparamagnetic nano iron oxide SPION and a polypeptide ligand modified on the surface of the superparamagnetic nano iron oxide SPION, and the polypeptide ligand is an N-terminal succinylated D-type neuropeptide Y series polypeptide ligand S-DNPY; the iron-based polypeptide probe for regulating and controlling the mitochondrial function competitively inhibits a mitochondrial succinylation behavior under the action of SIRT5 enzyme and NAD + coenzyme on mitochondria, in-situ self-assembly is performed after succinylation is performed, iron-based polypeptide probe aggregation is realized, a mitochondrial membrane is damaged, and the mitochondrial function is regulated and controlled. And abnormal oxidation is triggered, and cell apoptosis and autophagy clearance of damaged mitochondria are induced. The invention also discloses a medicine for inhibiting tumors, which comprises the iron-based polypeptide probe for regulating and controlling the mitochondrial function.

The present invention relates to peptide compounds that agonize the GIP, GLP-1 and neuropeptide Y2 (NPY2) receptors, agonists, processes for their preparation, pharmaceutical compositions thereof, and their medical use in the treatment and / or prevention of a variety of diseases such as obesity, diabetes, metabolic syndrome, and / or MASH / NASH. The peptide compounds of the invention are suitable for subcutaneous administration.

The application discloses a novel insect short neuropeptide sNPF analogue and application thereof in pests, and relates to the technical field of agriculture; the application provides a structural general formula of the novel insect short neuropeptide sNPF analogue, and the novel insect short neuropeptide sNPF analogue is applied to the prevention and treatment of aphids, thrips, Plutella xylostella and Spodoptera frugiperda. The terminal tyrosine Y, arginine R or leucine L residue is substituted and modified by using hydrophilic, hydrophobic, steric hindrance natural amino acids or unnatural amino acids and other groups on a lead compound, and the obtained novel insect short neuropeptide sNPF analogue can be used in the prevention and treatment of various pests.

The invention discloses a nilaparvata lugens muscle-friendly neuropeptide orcokinin-A and application of the nilaparvata lugens muscle-friendly neuropeptide orcokinin-A. The amino acid sequence of the neuropeptide orcokinin-A is as shown in SEQ ID NO. 2. The dsRNA (dsOKA) of the nilaparvata lugens muscle-friendly neuropeptide orcokinin-A has better gene silencing efficiency, and multiple experiments show that injection of 60ng of dsOKA can lead to incomplete ovarian development of female nilaparvata lugens adults, shortening of oviposition duration, significant reduction of oviposition amount, significant reduction of filial generation number and significant reduction of population growth index. The nilaparvata lugens muscle-friendly neuropeptide orcokinin-A can be used as an important molecular target for preventing and controlling nilaparvata lugens, is expected to fully exert the function of ecological prevention and control while inhibiting pests, and can be widely applied to crop breeding, biopesticide research and development and biological prevention and control.

The invention particularly discloses dendritic poly-L-lysine modified PACAP as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The PACAP-DPL provided by the invention effectively overcomes the defect of insufficient in-vivo stability of natural PACAP on the premise of not weakening the biological function of PACAP, provides a new technical approach for the application of PACAP neuropeptides in Alzheimer's disease, and has good research value and potential application prospect.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The present invention relates to analogues of insect neuropeptides having activity against insects, such as hemipteran, dipteran and / or lepidopteran insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

The present invention relates to insect neuropeptide compounds of the AKH family and analogs thereof having activity against insects, such as hemiptera, diptera, lepidoptera, cockroaches and / or coleopteran insects, such as aphids and fruit flies, and their use as insect control agents (e.g. Insecticides) and plant protection agents.

Described herein are radiotherapeutics that target tumor cells expressing the neuropeptide Y1 receptor (NPY1R) and their use in the treatment and / or diagnosis of cancer.